Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions

Three phase II randomized trials evaluated the safety/immunogenicity of two formulations of live-attenuated tetravalent dengue virus (TDEN) vaccine in dengue-endemic (Puerto Rico, Thailand) and non-endemic (US) regions (NCT00350337/NCT00370682/NCT00468858). We describe cell-mediated immune (CMI) res...

Full description

Bibliographic Details
Main Authors:	Philippe Moris, Kristen M. Bauer, Jeffrey R. Currier, Heather Friberg, Kenneth H. Eckels, Ines O. Esquilin, Robert V. Gibbons, Bruce L. Innis, Richard G. Jarman, Sriluck Simasathien, Peifang Sun, Stephen J. Thomas, Veerachai Watanaveeradej
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-09-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	live-attenuated tetravalent dengue candidate vaccine cellular-mediated immune responses dengue-primed and -unprimed populations
Online Access:	http://dx.doi.org/10.1080/21645515.2019.1581536

Similar Items

Clinical development update: 1st dengue vaccine candidate
by: Alain Bouckenooghe
Published: (2016-02-01)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
by: Mark Turner, et al.
Published: (2020-10-01)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
by: Judith Kirstein, et al.
Published: (2018-09-01)

Efficacy of tetravalent dengue vaccine: A systematic review and meta-analysis
by: Ashish Wasudeo Khobragade, et al.
Published: (2021-01-01)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
by: Kirill Nemirov, et al.
Published: (2023-08-01)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
by: Sanjay S. Patel, et al.
Published: (2023-08-01)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
by: Guy El Helou, et al.
Published: (2020-06-01)

A stochastic B cell affinity maturation model to characterize mechanisms of protection for tetravalent dengue vaccine constructs
by: Venkat R. Pannala, et al.
Published: (2023-07-01)

Moving forward with Takeda's live chimeric tetravalent dengue vaccine
by: Wilder-Smith, Annelies
Published: (2017)

A new tetravalent Dengue vaccine formulation based on four chimeric envelope domain III-capsid proteins induces a functional immune response in mice and non-human primates
by: Edith Suzarte, et al.

Vaccination With a Single Consensus Envelope Protein Ectodomain Sequence Administered in a Heterologous Regimen Induces Tetravalent Immune Responses and Protection Against Dengue Viruses in Mice
by: Ran Wang, et al.
Published: (2019-05-01)

Recent Developments in Recombinant Protein–Based Dengue Vaccines
by: Nagesh K. Tripathi, et al.
Published: (2018-08-01)

A recombinant live attenuated tetravalent vaccine for the prevention of dengue
by: Bruno Guy, et al.
Published: (2017-07-01)

Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series
by: Juliana Park, et al.
Published: (2020-03-01)

Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort
by: Cássia G. T. Silveira, et al.
Published: (2022-06-01)

The threat of climate change to non-dengue-endemic countries: increasing risk of dengue transmission potential using climate and non-climate datasets
by: Jung-Seok Lee, et al.
Published: (2019-07-01)

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines
by: Vannice, Kirsten S., et al.
Published: (2018)

Safety and immunogenicity of a single dose, live-attenuated ‘tetravalent dengue vaccine’ in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial
by: Lalitendu Mohanty, et al.
Published: (2022-04-01)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
by: Moffat Malisheni, et al.
Published: (2017-08-01)

Predictors of complicated dengue infections in endemic region of Pakistan
by: Ikram Waheed, et al.
Published: (2022-01-01)

A multi-country study of dengue vaccination modelling using econometric and GIS approaches in three dengue-endemic countries: Vietnam, Thailand, and Colombia
by: Lee, J
Published: (2018)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
by: Ramil R. Mintaev, et al.
Published: (2023-04-01)

Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand
by: Kriengsak Limkittikul, et al.
Published: (2019-01-01)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
by: Maia A Rabaa, et al.
Published: (2017-09-01)

Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine
by: Scott B. Halstead
Published: (2018-09-01)

Temporal distribution of dengue virus serotypes in Colombian endemic area and dengue incidence: re-introduction of dengue-3 associated to mild febrile illness and primary infection
by: Raquel Elvira Ocazionez, et al.
Published: (2006-11-01)

The dengue preface to endemic in mainland China: the historical largest outbreak by Aedes albopictus in Guangzhou, 2014
by: Lei Luo, et al.
Published: (2017-09-01)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
by: Shibadas Biswal, et al.
Published: (2021-06-01)

Dengue: 30 years of cases in an endemic area
by: Daniela Cristina Sensato Monteiro, et al.

Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
by: Wilder-Smith, Annelies, et al.
Published: (2016)

Community Vulnerability Map in Endemic Areas of Dengue Hemorrhagic Fever (DHF), Banyumas, Indonesia
by: Isna HIKMAWATI, et al.
Published: (2020-03-01)

Dengue and dengue hemorrhagic fever in the State of Pernambuco, 1995-2006 Dengue e febre hemorrágica do dengue no Estado de Pernambuco, 1995-2006
by: Marli Tenório Cordeiro, et al.
Published: (2007-12-01)

A tetravalent dengue nanoparticle stimulates antibody production in mice
by: Silva Elisângela F, et al.
Published: (2012-03-01)

Dengue virus /
by: Rothman, Alan L., editor
Published: (c201)

Dengue Fever
by: Gabriel Tadeo Rodriguez H
Published: (2022-12-01)

Nonlinear identification for dengue fever /
by: Herlina Abdul Rahim, 1973-, et al.
Published: (2009)

Analysis of entomological indicators and distribution of <i>Aedes aegypti</i> larvae in dengue endemic areas
by: Agung Sutriyawan, et al.
Published: (2023-09-01)

Frontiers in dengue virus research /
by: Hanley, Kathryn A., editor, et al.
Published: (c201)

Dengue en adultos
by: Victoria Frantchez, et al.
Published: (2016-03-01)

Dengue endêmico: o desafio das estratégias de vigilância Endemic dengue: surveillance strategy challenges
by: Keyla Belizia Feldman Marzochi
Published: (2004-10-01)